Cysteamine Bitartrate Delayed-Release for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Children (CyNCh)

Trial Profile

Cysteamine Bitartrate Delayed-Release for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Children (CyNCh)

Completed
Phase of Trial: Phase II/III

Latest Information Update: 07 Sep 2017

At a glance

  • Drugs Mercaptamine bitartrate (Primary)
  • Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
  • Focus Therapeutic Use
  • Acronyms CyNCh
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 25 Aug 2016 Results published in the Gastroenterology
    • 16 Nov 2015 Post-hoc analysis data published in a Raptor Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top